LUCENT (Ulcerative colitis)

The LUCENT 1 study is the first part of the LUCENT program of clinical studies, which will assess the impact of an investigational drug (mirikizumab) on the symptoms of Ulcerative Colitis (UC) in people who:

· Have active UC

· Are between 18 and 80 years old

· Have not been helped by previous or current treatments

To find out more about the LUCENT program, and see if you can take part, speak with your physician or contact the study team.